Cabergoline in acromegaly: A renewed role for dopamine agonist treatment?

European Journal of Endocrinology

Volumn 139, Issue 5, 1998, Pages 516-521

  Cozzi, R ^a   Attanasio, R ^a   Barausse, M ^a   Dallabonzana, D ^a   Orlandi, P ^a   Da Re, N ^a   Branca, V ^a   Oppizzi, G ^a   Gelli, D ^a  

^a OSPEDALE NIGUARDA CA GRANDA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CABERGOLINE; DOPAMINE; DOPAMINE RECEPTOR STIMULATING AGENT; GROWTH HORMONE; PROLACTIN; SOMATOMEDIN C;

ACROMEGALY; ADULT; AGED; ARTICLE; CLINICAL ARTICLE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; GASTROINTESTINAL SYMPTOM; HORMONE BLOOD LEVEL; HUMAN; HYPERPROLACTINEMIA; MALE; NIGHTMARE; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL;

EID: 0031767931     PISSN: 08044643     EISSN: None     Source Type: Journal    
DOI: 10.1530/eje.0.1390516     Document Type: Article

References (26)

1. Melmed S, Ho K, Klibanski A, Reichlin S & Thorner A. Clinical review: recent advances in pathogenesis, diagnosis and management of acromegaly. Journal of Clinical Endocrinology and Metabolism 1995 80 3395-5402.
2. Barkan AL. Acromegaly: diagnosis and therapy. Clinics in Endocrinology and Metabolism of North America 1989 18 177-310.
3. Di Salle E, Ornati G & Briatico G. FCE 21336, a new ergoline derivative with a potent and long-acting lowering effect on prolactin secretion in rats. Journal of Endocrinological Investigation 1982 5 Suppl 1 45.
4. Di Salle E, Giudici D & Ornati G. In vivo and in vitro duration of prolactin secretion inhibition by FCE 21336, pergolide and bromocriptine in rats. In Proceedings of the IVth International Congress on Prolactin, Charlottesville, SC, 1984, June 27-29: abstract 142.
5. Liuzzi A, Chiodini PG, Botalla L, Cremascoli G, Müller EE & Silvestrini F. Decreased plasma growth hormone (GH) levels in acromegalics following CB 154 (2-Br-alpha-ergocryptine) administration. Journal of Clinical Endocrinology and Metabolism 1974 38 910-914.
6. Plockinger U & Quabbe HJ. Evaluation of a repeatable depot bromocriptine preparation for the treatment of acromegaly. Journal of Endocrinological Investigation 1991 14 943-948.
7. Verde G, Chiodini PG, Liuzzi A, Cozzi R, Favales F, Botalla L, Spelta B, Dallabonzana D, Rainer E & Horowski H. Effectiveness of the dopamine agonist lysuride in the treatment of acromegaly and pathological hyperprolactinemic states. Journal of Endocrinological Investigation 1980 4 405-410.
8. Kleinberg DL, Boyd AE, Wardlaw S, Frantz AG, George A, Bryan N, Hilal S, Greising J, Hamilton D, Seltzer T & Sommers CJ. Pergolide for the treatment of pituitary tumors secreting prolactin or growth hormone. New England Journal of Medicine 1983 309 704-709.
9. Dallabonzana D, Liuzzi A, Oppizzi G, Cozzi R, Verde G, Chiodini PG, Rainer E, Dorow R & Horowski H. Chronic treatment of pathologic hyperprolactinemia and acromegaly with the new ergot derivative terguride. Journal of Clinical Endocrinology and Metabolism 1986 63 1002-1007.
10. Chiodini PG, Attanasio R, Cozzi R, Dallabonzana D, Oppizzi G, Orlandi P, Strada S & Liuzzi A. CV 205-502 in acromegaly. Acta Endocrinologica 1993 128 389-393.
11. Chiodini PG, Cozzi R, Dallabonzana D, Oppizzi G, Verde G, Petroncini MM, Liuzzi A, Boccardi E & Lancranjan I. Medical treatment of acromegaly - dopaminergic agonists and long-acting somatostatin. In Advances in Growth Hormone and Growth Factor Research, pp 423-436. Eds EE Müller, D Cocchi & V Locatelli. Roma, Milano: Pythagora Press and Berlin, Heidelberg: Springer Verlag, 1989.
12. 2 receptor gene expression in growth hormone-producing pituitary adenomas. In Proceedings of the 4th International Pituitary Congress 1996, San Diego, CA, June 16-18: abstract H5.
13. Ferrari C, Di Salle E, Persiani S, Piscitelli G & Strolin Benedetti M. Cabergoline (Dostinex), a long-acting prolactin lowering drug: a review of preclinical and clinical studies. Drugs of Today 1995 31 569-596.
14. Webster J, Piscitelli G, Polli A, Ferrari C, Ismail I & Scanlon MF for the Cabergoline Comparative Study Group. A comparison of cabergoline and bromocriptine in the treatment of hyperprolactinemic amenorrhea. New England Journal of Medicine 1994 331 904-909.
15. Melis GB, Gambacciani M, Paoletti AM, Mais V, Sghedoni D & Fioretti P. Reduction in the size of prolactin-producing pituitary tumors after cabergoline administration. Fertility and Sterility 1989 52 412-415.
16. Ferrari C, Paracchi A, Romano C, Gerevini G, Boghen M, Barreca A, Fortini P & Dubini A. Long-lasting lowering of serum growth hormone and prolactin levels by single and repetitive cabergoline administration in dopamine responsive acromegalic patients. Clinical Endocrinology 1988 29 467-476.
17. Muratori M, Arosio M, Gambino G, Romano C, Biella O & Faglia G. Use of cabergoline in the long-term treatment of hyperprolactinemic and acromegalic patients. Journal of Endocrinological Investigation 1997 20 537-546.
18. Colao A, Ferone D, Marzullo P, Di Sarno A, Cerbone G, Sarnacchiaro F, Cirillo S, Merola B & Lombardi G. Effect of different dopaminergic agents in the treatment of acromegaly. Journal of Clinical Endocrinology and Metabolism 1997 82 518-523.
19. Jackson SNJ, Fowler J & Howlett TA. Cabergoline treatment of acromegaly: a preliminary dose finding study. Clinical Endocrinology 1997 46 745-749.
20. Abs R, Verhelst J, Maiter D, Van Acker K, Nobels F, Coolens JL, Mahler C & Beckers A. Cabergoline in the treatment of acromegaly: a study in 64 patients. Journal of Clinical Endocrinology and Metabolism 1998 83 374-378.
21. Besser GM & Wass JAH. The medical management of acromegaly. In Secretory Tumors of the Pituitary Gland, pp 155-168. Eds PL Black, NT Zervas, EC Ridgway & JB Martin New York: Raven Press, 1984.
22. Robbins RJ. Depot somatostatin analogs - a new first line therapy for acromegaly. Journal of Clinical Endocrinology and Metabolism 1997 82 15-17.
23. Caron P, Morange-Ramos I, Cogne M & Jacquet P. Three year follow-up of acromegalic patients treated with intramuscular slow-release lanreotide. Journal of Clinical Endocrinology and Metabolism 1997 82 18-22.
24. Flogstad AK, Halse J, Bakke S, Lancranjan I, Marbach P, Bruns Ch & Jervell J. Sandostatin LAR in acromegalic patients: long-term treatment. Journal of Clinical Endocrinology and Metabolism 1997 8223-31.
25. Ferrari C, Abs R, Bevan JS, Brabant G, Ciccarelli E, Motta T, Mucci M, Muratori M, Musatti L, Verbessem G & Scanlon MF. Treatment of macroprolactinomas with cabergoline: a study of 85 patients. Clinical Endocrinology 1997 46 409-413.
26. Oppizzi G, Liuzzi A, Chiodini PG, Dallabonzana D, Spelta B, Silvestrini F, Borghi G & Tonon C. Dopaminergic treatment of acromegaly: different effects on hormone secretion and tumor size. Journal of Clinical Endocrinology and Metabolism 1984 580 988-992.